AstraZeneca (AZN 5.38%) may pay a heft dividend, but the company has been facing a number of headwinds and regulatory setbacks lately. In the following video from the Motley Fool's health-care show, Market Checkup, analysts David Williamson and Max Macaluso discuss the partnerships that this company has been forming to boost its pipeline and the key to accelerating its turnaround.
Free Article
AstraZeneca: Lost Stock or Cheap Turnaround?
By Max Macaluso and Dave Williamson
–
Sep 19, 2013 at 7:04PM
NASDAQ: AZN
AstraZeneca Plc
Market Cap
$221B
Today's Change
(5.38%) $3.83
Current Price
$75.03
Price as of April 25, 2024, 4:00 p.m. ET
Can this big pharma company return to growth?
David Williamson and Max Macaluso, Ph.D. have no position in any stocks mentioned. The Motley Fool recommends and owns shares of Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Related Articles
AstraZeneca Plc (AZN) Q1 2024 Earnings Call Transcript
Move Aside, Eli Lilly and Novo Nordisk. Wall Street Thinks This Stock Will Be a Bigger Winner Over the Next 12 Months.
AstraZeneca Plc (AZN) Q4 2023 Earnings Call Transcript
History Says the Nasdaq Will Keep Soaring in 2024. Here's the Surprising Megacap Stock Wall Street Thinks Will Be the Biggest Winner.
AstraZeneca Just Joined the AI Drug Development Craze, but Is It a Buy in 2024?
619%
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.